Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

1.

Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.

Nagane M, Nishikawa R, Narita Y, Kobayashi H, Takano S, Shinoura N, Aoki T, Sugiyama K, Kuratsu J, Muragaki Y, Sawamura Y, Matsutani M.

Jpn J Clin Oncol. 2012 Oct;42(10):887-95. Epub 2012 Jul 27.

PMID:
22844129
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Bevacizumab for the treatment of high-grade glioma.

Khasraw M, Simeonovic M, Grommes C.

Expert Opin Biol Ther. 2012 Aug;12(8):1101-11. doi: 10.1517/14712598.2012.694422. Epub 2012 Jun 5. Review.

PMID:
22663137
[PubMed - indexed for MEDLINE]
3.

Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.

Narita Y.

Jpn J Clin Oncol. 2013 Jun;43(6):587-95. doi: 10.1093/jjco/hyt051. Epub 2013 Apr 12. Review.

PMID:
23585688
[PubMed - indexed for MEDLINE]
Free Article
4.

Bevacizumab at recurrence in high-grade glioma.

Salmaggi A, Gaviani P, Botturi A, Lamperti E, Simonetti G, Ferrari D, Silvani A.

Neurol Sci. 2011 Nov;32 Suppl 2:S251-3. doi: 10.1007/s10072-011-0799-6. Review.

PMID:
21987287
[PubMed - indexed for MEDLINE]
5.

Bevacizumab in glioblastoma multiforme.

Specenier P.

Expert Rev Anticancer Ther. 2012 Jan;12(1):9-18. doi: 10.1586/era.11.179. Review.

PMID:
22149428
[PubMed - indexed for MEDLINE]
6.

Bevacizumab: a treatment option for recurrent glioblastoma multiforme.

Buie LW, Valgus J.

Ann Pharmacother. 2008 Oct;42(10):1486-90. doi: 10.1345/aph.1L030. Epub 2008 Sep 2. Review.

PMID:
18765835
[PubMed - indexed for MEDLINE]
7.

Update on bevacizumab and other angiogenesis inhibitors for brain cancer.

Rinne ML, Lee EQ, Nayak L, Norden AD, Beroukhim R, Wen PY, Reardon DA.

Expert Opin Emerg Drugs. 2013 Jun;18(2):137-53. doi: 10.1517/14728214.2013.794784. Epub 2013 May 14. Review.

PMID:
23668489
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk